Medical Sciences Forum

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Other

8 pages, 411 KB

Open AccessProceeding Paper

Targeting the Tumor Microenvironment with Radiolabeled Antibodies: Bridging Immunotherapy and Molecular Imaging

by Krishnaveni Manubolu and Raveesha Peeriga

Med. Sci. Forum 2025, 40(1), 1; https://doi.org/10.3390/msf2025040001 - 26 Nov 2025

Viewed by 936

Abstract

Radiolabeled monoclonal antibodies represent a promising approach to integrate molecular imaging with immunotherapy for cancer diagnosis and treatment. These antibodies target immune checkpoints and tumor-associated antigens, enabling non-invasive visualization of tumor dynamics through PET and SPECT imaging. Evidence from preclinical and clinical studies suggests that such imaging can provide insights into antibody distribution, immune cell infiltration, and potential treatment responses within the tumor microenvironment. By combining diagnostic and therapeutic capabilities, antibody-based theranostics offer opportunities for personalized treatment planning and understanding mechanisms of resistance. This review highlights current advances in antibody-based molecular imaging, discusses challenges in translation, and explores future directions for integrating imaging with immuno-oncology strategies to improve patient outcomes. Radiolabeled antibodies allow non-invasive assessment of tumor–immune interactions, supporting adaptive treatment planning and bridging immunotherapy with molecular imaging. Full article

(This article belongs to the Proceedings of The 1st International Online Conference by Antibodies)

► Show Figures

Graphical abstract

10 pages, 785 KB

Open AccessProceeding Paper

Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

by Angel Justiz-Vaillant

Med. Sci. Forum 2025, 40(1), 2; https://doi.org/10.3390/msf2025040002 - 11 Dec 2025

Viewed by 2359

Abstract

Antibody–drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. These engineered molecules are designed to selectively deliver cytotoxic agents to specific cells, thereby reducing off-target toxicity and enhancing therapeutic efficacy. In oncology, ADCs have already demonstrated significant clinical success, particularly in the treatment of hematological malignancies and solid tumors. Agents such as trastuzumab emtansine and brentuximab vedotin exemplify how ADCs can effectively target cancer cells while limiting damage to healthy tissues. This review comprehensively explores the key aspects of the use of ADCs in autoimmune disorders, which is an evolving field in immunotherapy. Full article

(This article belongs to the Proceedings of The 1st International Online Conference by Antibodies)

► Show Figures

Figure 1

18 pages, 248 KB

Open AccessConference Report

Abstracts of the 1st International Online Conference by Antibodies

by Arne Skerra

Med. Sci. Forum 2025, 40(1), 3; https://doi.org/10.3390/msf2025040003 - 12 Dec 2025

Viewed by 758

Abstract

Mattias Collin ¹, Berit Olofsson ¹, Andreas Naegeli ² and Pontus Nordenfelt ¹ [...] Full article

(This article belongs to the Proceedings of The 1st International Online Conference by Antibodies)

8 pages, 406 KB

Open AccessProceeding Paper

Detection of Anti-HEV IgM and IgG Antibodies Among Antenatal Women Attending a Tertiary Care Center

by Abdul Qadeer, Mariya Azam and Basit Abdul

Med. Sci. Forum 2025, 40(1), 4; https://doi.org/10.3390/msf2025040004 - 23 Mar 2026

Viewed by 368

Abstract

Hepatitis E virus (HEV) is recognized as one of the leading causes of acute viral hepatitis (AVH) in developing countries, where it is primarily transmitted through the consumption of contaminated food and water. Although often self-limiting, HEV infection poses a significant public health concern, particularly among pregnant women, due to its potential complications. The present study aimed to determine the seroprevalence of HEV infection in asymptomatic antenatal women attending a tertiary care center in South Punjab, Pakistan. A total of 100 asymptomatic pregnant women were screened for anti-HEV antibodies (IgM and IgG) using an ELISA kit (DIA PRO, Italy). The overall seropositivity rate was found to be 12%, indicating prior exposure to HEV infection in this cohort. Specifically, IgG antibodies were detected in 6% of women and IgM antibodies in 5%, while two women showed evidence of both IgG and IgM positivity, suggestive of recent or ongoing infection. Notably, the majority of participants reported reliance on untreated water sources irrespective of educational background, highlighting environmental risk factors. Although HEV is generally self-limiting, these findings underscore the importance of routine serological screening in antenatal populations to prevent adverse pregnancy outcomes. In addition, increased community awareness regarding transmission routes and preventive measures is essential. Given the scarcity of regional data, this study emphasizes the need for larger-scale epidemiological investigations to better understand the burden of HEV in South Punjab, Pakistan. Full article

(This article belongs to the Proceedings of The 1st International Online Conference by Antibodies)

► Show Figures

Journal Menu

Journal Browser

Med. Sci. Forum, 2025, IOCAB 2025

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI